Asia Fresh News

Asia Fresh Stories

Archive for June 12th, 2014

Merial appoints Fabian Kausche to lead Global Research & Development

leave a comment »

– Veteran of animal health brings depth of expertise to Merial’s R&D organization –

LYON, France, June 10, 2014 /PRNewswire/ — Merial, the animal health division of Sanofi, today announced that Fabian Kausche will be leading the company’s global research and development (R&D) efforts, effective June 9, 2014. Dr. Kausche brings to the company a wide range of global experience in pharmaceutical and biological R&D and business leadership positions, at both human and animal health companies.

Dr. Kausche joins Merial after 10 years at Novartis, where he was most recently global Head of R&D for Animal Health. Prior to this, he served as Senior Vice President and global Head of R&D for the Over-The-Counter Human Health Division, and as Vice President of Sales for the US Companion Animal business, successfully increasing year-over-year sales. Before joining Novartis, he was a clinical research scientist for the Upjohn Company and senior director for clinical development of biologicals for Pfizer Animal Health.

“Fabian’s expertise and proven track record in product development with approvals around the world, in addition to his business and organizational leadership, deliver a rare combination of talents and knowledge,” said Carsten Hellmann, CEO of Merial “With our recent introductions of groundbreaking products like NexGard™ and Longrange®, and with an extensive pipeline in place, Fabian’s leadership will further accelerate our R&D efforts for continued and sustainable growth and success.”

As the new Global Head of R&D, Dr. Kausche will be based in Duluth, Ga., USA, with responsibility for advancing Merial’s leadership in the discovery and development of innovative vaccines and therapies for companion and production animals. He will lead Merial’s global R&D team, including more than 700 scientists and support staff at R&D sites around the world, to advance more than 50 projects currently in development for a variety of animal species.

A German citizen, Fabian holds a PhD in veterinary medicine from the Veterinary School in Hannover Germany, a Masters of Science degree from Iowa State University (US), and completed an Advanced Management Program at Harvard Business School.

Fabian Kausche will be a member of the Merial Leadership Team and will report to Merial CEO Carsten Hellmann.  He will also be a member of the Sanofi R&D Leadership Team.

Written by asiafreshnews

June 12, 2014 at 3:52 pm

Posted in Uncategorized

Merck Serono Announces FDA Clearance for Auxogyns Early Embryo Viability Assessment (Eeva(R)) System 

leave a comment »

— FDA clearance validates Eeva System, which enables in-vitro fertilization (IVF) clinicians to offer the proprietary Eeva Test and further demonstrates commitment by Merck Serono and Auxogyn to bring innovative technologies to the IVF community

— Eeva Test first-of-a-kind prognostic, non-invasive test that provides IVF clinicians objective information regarding embryo development to help optimize treatment plans for their patients

DARMSTADT, Germany /PRNewswire/ — Merck Serono, the biopharmaceutical division of Merck, today announced that the proprietary Early Embryo Viability Assessment (Eeva(R)) System of Merck Serono´s strategic partner Auxogyn received clearance from the U.S. Food and Drug Administration (FDA) through its de novo classification process, a regulatory pathway for select novel, low-to-moderate risk medical devices that are first-of-a-kind. Merck Serono is the exclusive commercial partner of Auxogyn, Inc., for the Eeva System in Europe and Canada.

The Eeva Test, used adjunctively to traditional morphology, is the first and only prognostic, non-invasive embryo test to receive clearance from the FDA. The Eeva Test utilizes proprietary software that automatically analyzes embryo development against scientifically derived cell-division timing parameters captured through continual video imaging. This objective information provided to reproductive endocrinologists and embryologists helps to optimize treatment plans for their patients.

“The FDA clearance of the Eeva System reinforces the value of the applicability of the Eeva Test in the IVF lab and may improve IVF outcomes. It marks another significant and exciting milestone in our continued collaboration with Auxogyn to further support the clinical development and commercialization of their Eeva Test,” said Meeta Gulyani, Head of Strategy and Global Franchises at Merck Serono. “We, therefore, welcome this further validation for the potential of the Eeva Test to objectively identify the embryos with the highest implantation potential, which may ultimately improve patient outcomes.”

The Eeva System received the CE Mark in 2012 and has been commercially available in the European Union ever since, and more recently in Canada since 2013. The potential of the Eeva System led to an expansion of the original partnership agreement to include a licensing agreement between Merck and Auxogyn, announced in April 2014 for the exclusive rights to commercialize the Eeva Test in Europe and Canada. Auxogyn plans to commercialize the Eeva Test in the United States later this year.

“Were excited to receive the de novo FDA clearance for the Eeva System and believe this marks a significant milestone in the field of IVF,” said Lissa Goldenstein, president and CEO of Auxogyn. “We have followed a rigorous, years-long clinical validation process and regulatory pathway to bring the Eeva Test to market. Our clearance provides a new level of confidence to IVF clinicians who, for the first time, have quantitative information that can be used in addition to traditional morphology to aid in deciding which embryo or embryos to transfer.”

According to the European Society of Human Reproduction and Embryology (ESHRE), approximately five million additional babies have been born worldwide since 1978 as a result of assisted reproduction technologies (ART), like IVF.[1] This trend may increase due to advancements in ART and IVF technologies such as the Eeva Test.


— European Society of Human Reproduction and Embryology. (2012). The worlds number of IVF and ICSI babies has now reached a calculated total of 5 million [Press release]. Retrieved from

About Auxogyn

Auxogyn is revolutionizing the field of reproductive medicine by translating scientific discoveries in early embryo development into clinical tools. The companys flagship product, the Eeva Test, delivers consistent, objective and quantitative information regarding embryo viability that IVF clinicians and infertility patients can use to make important treatment decisions. Auxogyn is privately held and funded by Kleiner Perkins Caufield & Byers, MS Ventures, SR One and TPG Biotech.

For more information regarding Auxogyn, please visit

About Eeva

Auxogyns non-invasive early embryo viability assessment (Eeva) Test when used adjunctively to traditional morphology may improve IVF outcomes by providing IVF clinicians and patients with objective information on embryo viability. The Eeva System utilizes proprietary software that automatically analyzes embryo development against scientifically and clinically validated cell-division timing parameters. With Eevas quantitative data on each embryos potential development, IVF clinicians can optimize the treatment path for their patients undergoing IVF procedures.

Auxogyn received CE mark for Eeva in July 2012, and it is currently available for use in selected countries in the EU.

For more information regarding Eeva, please visit

About Merck Serono

Merck Serono is the biopharmaceutical division of Merck. With headquarters in Darmstadt, Germany, Merck Serono offers leading brands in 150 countries to help patients with cancer, multiple sclerosis, infertility, endocrine and metabolic disorders as well as cardiovascular diseases. In the United States and Canada, EMD Serono operates as a separately incorporated subsidiary of Merck Serono.

Merck Serono discovers, develops, manufactures and markets prescription medicines of both chemical and biological origin in specialist indications. We have an enduring commitment to deliver novel therapies in our core focus areas of neurology, oncology, immuno-oncology and immunology.

For more information, please visit

All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to to register online, change your selection or discontinue this service.

Merck is a leading company for innovative and top-quality high-tech products in the pharmaceutical and chemical sectors. With its four divisions Merck Serono, Consumer Health, Performance Materials and Merck Millipore, Merck generated total revenues of EUR 11.1 billion in 2013. Around 38,000 Merck employees work in 66 countries to improve the quality of life for patients, to further the success of customers and to help meet global challenges. Merck is the worlds oldest pharmaceutical and chemical company – since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70 percent interest, the founding family remains the majority owner of the company to this day. Merck, Darmstadt, Germany is holding the global rights to the Merck name and brand. The only exceptions are Canada and the United States, where the company is known as EMD.
SOURCE Merck Serono

Written by asiafreshnews

June 12, 2014 at 3:48 pm

Posted in Uncategorized

Amelie Vidal-Simi, President and CEO of Henkel France, Is Awarded the 2014 Prix EDHEC

leave a comment »

PARIS /PRNewswire/ — EDHEC Business School, Paris 5th of June 2014 – Ms Amelie Vidal-Simi received the 2014 Prix EDHEC – an annual award presented by the EDHEC Alumni Association – at a ceremony on the business school’s Paris campus.

To view the Multimedia News Release, please click:

Since 1983, the award has been presented to the alumna our alumnus who, through their professional or personal actions, has done the most to promote EDHEC’s reputation locally, nationally and internationally.

Ms Vidal-Simi took on her new duties as president and CEO of Henkel France 1 March 2013.

Ms Vidal-Simi started her career with Henkel in 1990 as a product manager overseeing different brands of detergents. She was named head of marketing in 1996, and she was named director of marketing in 2000. As part of her mission as head of sales, she also oversaw key international accounts such as Carrefour World Trade, Auchan International and IRTS.

In October 2009, she was named general director of the division of glues and adhesives for the public as well as building professionals, and joined the executive committee for Henkel France.

Since 2012, Ms Vidal-Simi has also managed glues and adhesives for the public and professionals for Henkel Benelux.

With the acceptance of the 2014 Prix EDHEC, Ms Vidal-Simi succeeds last year’s winner Michael Burke, EDHEC 1980, the President and CEO of Louis Vuitton.

“Amelie Vidal-Simi embodies the success and adaptability of our graduates in international companies that we hope to instil in our graduates. Our Alumni are the best ambassadors we have as they exemplify the superior quality of the EDHEC Business School education and the values of responsibility and innovation our school has passed on to its graduates for more than 100 years,” said Olivier Oger, Chairman and CEO of the EDHEC Group.

EDHEC Alumni by the numbers

EDHEC Alumni is an association that represents the graduates of the EDHEC Business School

EDHEC Alumni represents 25 000 graduates in 120 countries

EDHEC Alumni hosts 400 events each year

EDHEC alumni provide career counselling to 300 undergraduates each year

EDHEC alumni provide

8 000 job offers to new graduates each year

Written by asiafreshnews

June 12, 2014 at 1:54 pm

Posted in Uncategorized

TIBCO Jaspersoft Launches Visualize.js Framework for Embedding Analytics and Data Visualisations

leave a comment »

  • 5.6 Release also Advances Big Data Access, Performance, Analytics and Reporting

PALO ALTO, Calif./PRNewswire/ — TIBCO Software Inc. (NASDAQ: TIBX) today announced that its Jaspersoft® group, creating the “Intelligence Inside” applications and business processes, has released Visualize.js, a JavaScript framework for advanced embedding of visualisations and reports in applications. The new framework, which is available with the newly released TIBCO Jaspersoft 5.6 platform, delivers more control, simplicity and power for application developers by combining the power of the complete Jaspersoft analytic server with the simplicity and control of JavaScript. In addition to Visualize.js, Jaspersoft introduced a series of updates to its flagship platform. Version 5.6 of the Jaspersoft platform includes virtualised blending of relational and Big Data sources such as MongoDB, Hadoop and Cassandra, more powerful analytic calculations and visualisations, and new interactive reporting features.


With Visualize.js, anyone building a web application can more easily include powerful analytics as an integrated experience. Developers can now embed highly interactive visualisations and reports with more control and power than previously available using iFrames, charting libraries or other BI vendor solutions. Visualize.js leverages the REST APIs of JasperReports® Server for built-in services such as data connectivity, repository access, in-memory analytics, and visualisation design. Visualize.js ushers in the next generation of embedded analytic platforms with its on-premises or cloud deployment options, low-cost subscription or utility pricing, and comprehensive feature set which delivers unmatched control and simplicity.

Early Visualize.js user, Raj Chary, vice president of technology and architecture at Triumph Learning, noted, “Our Web-based application, GET Waggle, makes it simple for teachers and school administrators to track and measure students’ progress and growth on skills and standards. Data visualisations and analytics are a key component of our product platform, and the ability to take immediate actions on key metrics makes it a very powerful tool for our users. We needed visualisations in our product to be a delightful, not a daunting experience. Jaspersoft, with Visualize.js, provided a very rich way to integrate and build reports. This allowed us to easily embed the full power of the platform into GET Waggle to create an experience that makes the data actionable for our users.”

Jaspersoft 5.6

Version 5.6 of the Jaspersoft BI platform is designed to help more business users become capably analytic, with advances in key areas such as Big Data connectivity, platform performance, analytics and reporting. In summary, the new features in version 5.6 include:

  • Federated query connectors to virtually blend relational data with data from companies such as MongoDB, Hadoop or Cassandra;
  • Improved native connectors for direct access to companies such as MongoDB, Hadoop and Cassandra for real-time reporting;
  • New analytic calculations and functions allow users to build their own algorithms for more advanced analysis of data;
  • New chart types including spider, bubble, and dual-level pie charts; and
  • Enhanced interactive reporting functionality, including improved zoom and search capabilities.

“More than ever, analytics is now a thing that you do and not a place that you go,” said Brian Gentile, senior vice president and general manager, TIBCO Jaspersoft. “The Jaspersoft 5.6 platform advancements, when combined with the new Visualize.js framework, enable any web application to seamlessly embed and control advanced analytic functionality. This enables just the right amount of data — no more and no less — to be presented directly in an application, making everyone more capably analytic.”

Additional Resources

TIBCO Software Inc. (NASDAQ: TIBX) is a global leader in infrastructure and business intelligence software. Whether it’s optimising inventory, cross-selling products, or averting crisis before it happens, TIBCO uniquely delivers the Two-Second Advantage® — the ability to capture the right information at the right time and act on it pre-emptively for a competitive advantage. With a broad mix of innovative products and services, TIBCO is the strategic technology partner trusted by businesses around the world. Learn more about TIBCO at

TIBCO, Jaspersoft, JasperReports Server, Visualize.js, Two-Second Advantage and TIBCO Software are trademarks or registered trademarks of TIBCO Software Inc. and/or its subsidiaries in the United States and/or other countries. All other product and company names and marks mentioned in this document are the property of their respective owners and are mentioned for identification purposes only.

Media Contact:
Jane Gideon
Incendio International for Jaspersoft
+1 415 682 9292

Source: TIBCO Software Inc.

Written by asiafreshnews

June 12, 2014 at 12:26 pm

Posted in Uncategorized

RuiYi and iHuman Institute Form Collaboration to Identify Novel Antibodies Targeting GPCRs

leave a comment »

New antibodies generated with RuiYi’s iCAPS technology to explore GPCR structure and function

LA JOLLA, Calif. and SHANGHAI, June 11, 2014 /PRNewswire/ — RuiYi, a global therapeutic innovation leader, and iHuman Institute at ShanghaiTech University announced today a new research collaboration applying RuiYi’s iCAPS (Intermembranous Conformation Antigen Presenting System) technology to create novel monoclonal antibodies with specific binding to G protein coupled receptors (GPCRs) to investigate the biological function and structure of GPCRs.

“As mediators of cellular communication, GPCRs and their related intracellular proteins play a central role in human biology and are important targets in mediating physiological processes to treat disease,” said Ray Stevens, Ph.D., founding director of iHuman Institute and scientific founder of RuiYi. “The evolution and power of RuiYi’s iCAPS technology enables the generation of antibodies to GPCRs with great selectivity, which can be used not only for antibody therapeutic development but also for probing the structure, function, chemical probe discovery, and signaling pathways of GPCRs.”

Dr. Stevens founded the iHuman Institute in 2012 to focus on human cell signaling research. In 2007, the Stevens Laboratory and his colleagues opened the door to multiple high-resolution structures of human GPCRs with follow on functional studies. His efforts have produced a significant amount of the current GPCR structure-function data available to the scientific community.

“At the iHuman Institute, the researchers integrate multiple tools for scientific discovery for advancing human cell signaling research and drug discovery,” said Dr. Jie Yin, vice president and provost of ShanghaiTech University. “I look forward to seeing the collaboration help to decipher the mysteries of GPCR signaling.”

“Bringing RuiYi’s iCAPS technology to iHuman Institute will synergize research efforts in elucidating GPCR structure-function and how structure affects the physiological function,” said Paul Grayson, president and CEO of RuiYi. “The knowledge gained from this collaboration will not only advance the scientific understanding of human cell signaling but also help us better identify selective antibody inhibitors or activators for more effective therapeutics.”

Written by asiafreshnews

June 12, 2014 at 11:56 am

Posted in Uncategorized

RuiYi Closes $4 Million Venture Loan from Silicon Valley Bank

leave a comment »

LA JOLLA, Calif. and SHANGHAI, June 11, 2014 /PRNewswire/ — RuiYi, Inc., a global therapeutic innovation leader, announced today the close of a $4 million debt financing from Silicon Valley Bank to advance a pipeline of novel monoclonal antibodies (mAb) targeting G protein coupled receptors (GPCRs). RuiYi plans to file an IND and initiate clinical trials in multiple countries in 2015 for the company’s lead asset, RYI-008, a novel anti-IL-6 mAb for rheumatoid arthritis and cancer. RuiYi will also be advancing RYI-018 into preclinical studies. Identified via RuiYi’s iCAPS™ platform, RYI-018 is a first-in-class monoclonal antibody to cannabinoid receptor 1 (CB-1), a commercially validated but previously intractable drug target.

“This non-dilutive financing from Silicon Valley Bank will support multiple pipeline advancements, including moving RYI-018 through protein engineering for IND-enabling studies, bringing RYI-008 into clinical trials and discovering additional drug candidates from our iCAPS platform,” said Paul Grayson, president and CEO, RuiYi. “Drug discovery and development is, by nature, a cost-intense business. To develop innovative, new medicines that can help patients and also be accepted by payers around the world, we are conscientious about using our capital most efficiently.”

Lei Lu, Senior Vice President of Finance & Operations added, “We appreciate this additional funding mechanism SVB brought to us. With RuiYi’s strategy of controlled burn and development through regional partnering, this funding, together with the $15m Series B financing closed in March, 2014, provides the company significant additional runway. The key to a successful financing is generating the appropriate combination of equity financing and debt to reach substantial valuation inflection points. Silicon Valley Bank has been a vital part of this equation for multiple industries for decades.”

“Providing companies such as RuiYi with capital to get through key value creating corporate milestones is an important way for us to expand SVB’s relationship with our clients,” said Mike White, managing director, Silicon Valley Bank. “By developing novel therapeutics, RuiYi is a trailblazer in finding innovative ways to help patients around the world. We are pleased to provide RuiYi with additional financing flexibility so that they can bring new medicines to market with a capital efficient path.”

RuiYi’s first drug candidate, RYI-008, a novel anti-IL-6 monoclonal antibody, has a unique pharmacologic profile with the potential to define a new paradigm in the treatment of autoimmune diseases and cancer. Last year, RuiYi announced a collaboration with Genor BioPharma to develop the antibody in China. In addition, from iCAPS, RuiYi has identified another drug candidate, RYI-018 for peripheral disease, which is highly specific and selective to CB-1, a known therapeutically relevant and commercially validated GPCR target.

Written by asiafreshnews

June 12, 2014 at 11:41 am

Posted in Uncategorized

ooVoo Releases ooVoo for Windows Phone Store

leave a comment »

NEW YORK, June 11, 2014 /PRNewswire/ — ooVoo today announced that it has launched ooVoo for Windows Phone. ooVoo is a social video chat platform that lets users instantly connect to their closest friends through HD video. ooVoo is free to use, and supports one-on-one and group video calling for up to 12 people. Adding Windows Phone to its list of platforms is an exciting milestone, reinforcing ooVoo’s company mission to power every video interaction and shared online experience across the globe.

Photo –

“ooVoo is excited to have worked together with Microsoft Corp. to provide our Windows Phone users with a great experience,” said Rajesh Midha, Head of Product. “Our Windows Phone app is fully native to the platform, and by bringing the best of our product to a whole new suite of supported devices, we continue to seamlessly connect friends and family everywhere.”

“Windows Phone is backed by an incredible app ecosystem that takes advantage of the platform’s unique features and design,” said Steve Guggenheimer, Corporate Vice President of Microsoft’s Developer & Platform Evangelism Group. “ooVoo is a great example of the kind of rich applications that enables users to connect in new and interesting ways.”

ooVoo has more than 100 million registered users worldwide, and already supports platforms across iOS, Android, Mac and PC. ooVoo for Windows Phone features free 12-way group video chat, voice calling, instant messaging, echo cancellation for crystal-clear audio, and Superclear™ video—ooVoo’s proprietary technology which adjusts for packet-loss on low-bandwidth video calls. To learn more about ooVoo’s high-quality HD video calling and to see a full list of features supported by Windows Phone, visit

Download ooVoo from the Windows Phone Store:

Written by asiafreshnews

June 12, 2014 at 10:54 am

Posted in Uncategorized

Swisslog Recognized with 2013 Supplier Excellence Award by Texas Instruments

leave a comment »

SINGAPORE, June 2, 2014 /PRNewswire/ — Swisslog, a global provider of integrated logistics solutions for warehouses, distribution centers and hospitals, has received the Texas Instruments (TI) 2013 Supplier Excellence Award. The annual award honors companies whose dedication and commitment in supplying products and services meet TI’s high standards for excellence. Swisslog is one of the companies from an elite group of 12 suppliers chosen for their exemplary performance in the areas of Cost, Environmental & Social Responsibility, Technology, Responsiveness, Assurance of Supply, and Quality.

From left to right: Pieter Marseille, Global Product Distribution Manager, Texas Instruments; Koh Seng Teck, Head of WDS Southeast Asia, Swisslog, Larry Tan, President, Texas Instruments Asia
From left to right: Pieter Marseille, Global Product Distribution Manager, Texas Instruments; Koh Seng Teck, Head of WDS Southeast Asia, Swisslog, Larry Tan, President, Texas Instruments Asia

Swisslog was commissioned by TI at the end of 2011 to implement the intralogistic automation for TI’s Product Distribution Center (PDC), located within Free Trade Zone in Changi, Singapore. The facility manages products arriving from 20 inbound countries and orders are consolidated and shipped to 54 outbound countries. The installation of the AutoStore goods-to-person robotic storage and order fulfillment solution has improved accuracy and space efficiency. The significant space utilization allowed 4 times the volume of products to be stored within same footprint and result in significant boost in productivity. Currently the automation managed a huge portion of volume from total shipment whereby the majority of the outbound shipments are from the AutoStore system.

“We are honored that our contribution has been recognized by Texas Instruments,” said Koh Seng Teck, Swisslog Head of WDS Southeast Asia region. “The recognition was built on our continuous commitment to help Texas Instruments meet their supply chain goals by reducing costs and increasing productivity of their operation.”

“We look to Swisslog Singapore Pte Ltd., as a key business partner, to help us achieve our priorities through outstanding execution, quality and performance. Swisslog Singapore Pte Ltd. has demonstrated outstanding commitment in helping us achieve higher productivity and greater efficiency in our supply chain operations. The AutoStore® system has given us better inventory control and along with greater speed and accuracy to help us support our Analog and Embedded Processing customers,” said Rob Simpson, TI Vice President of Worldwide Procurement and Logistics.

A management team from TI Leadership and the Worldwide Procurement and Logistics team presented the award to Swisslog WDS Head of Southeast Asia, Mr. Koh Seng Teck at an award ceremony on the 14th of May 2014. In addition, a formal announcement from Texas Instruments about this award can be found on their website:


Swisslog Singapore Pte Ltd
Koh Seng Teck
Head of WDS Southeast Asia
Tel: +65-6280-0600

About Swisslog

Swisslog is a global provider of integrated logistics solutions for warehouses, distribution centers and hospitals. With years of experience in the development and implementation of integrated logistics solutions, Swisslog provides the expertise that customers in more than 50 countries around the world rely on.

Headquartered in Buchs/Aarau, Switzerland, Swisslog currently employs over 2 100 staff in 20 countries worldwide. The group’s parent company, Swisslog Holding AG, is listed on the SIX Swiss Exchange (security number: 1232462, Telekurs: SLOG, Reuters: SLOG.S). Note: Swisslog refers to an order as “major order” if its financial volume exceeds the threshold of MCHF 20.

Source: Swisslog

Written by asiafreshnews

June 12, 2014 at 12:13 am

Posted in Uncategorized